Jump to page content

BeLOVE is an acronym for „Berlin Longterm Observation of Vascular Events“ and represents a so called cohort study. Within the framework of BeLOVE, data and biomaterials will be collected prospectively, i.e. from the time a patient is enrolled in the study onward. It is a non-interventional study, i.e. it does not interfere with the treatment of the study participants
Cardiovascular diseases belong to the worldwide most common diseases and contribute fundamentally to the burden of disease in our society. The analysis of as much study and patient data as possible, investigations on a wide variety of biomaterials and the performance of medical examinations may help to improve our understanding of the development of these diseases. In future, this may contribute to the faster identification of cardiovascular diseases, improved treatment of patients and the development of more effective preventive measures and therapies.
Patients with acute myocardial infarction, after acute decompensated heart failure, after acute stroke, or patients without one of these events but a comparably very high risk for cardiovascular diseases (type 2 diabetes mellitus, hypertension, hyperlipidemia) will be enrolled in this study. The objective of BeLOVE is to comprehensively investigate correlations between different disease states (cardiovascular and metabolic diseases such as heart attack, stroke, heart failure, diabetes, renal failure), to develop predictive models for the future course of the disease and to identify biomarkers that play a role in the development and course of cardiovascular diseases as well as metabolic diseases. For this purpose, the establishment of a large study cohort is mandatory.